PMID- 37732117
OWN - NLM
STAT- MEDLINE
DCOM- 20230922
LR  - 20230922
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 14
DP  - 2023
TI  - Prevalence of vitamin B12 deficiency in type 2 diabetic patients taking 
      metformin, a cross-sectional study in primary healthcare.
PG  - 1226798
LID - 10.3389/fendo.2023.1226798 [doi]
LID - 1226798
AB  - BACKGROUND: Several studies documented that metformin use contributes to vitamin 
      B12 deficiency in patients with type 2 diabetes mellitus (T2DM). However, there 
      has been a lack of data assessing this issue in Jordan. AIMS: Assess the vitamin 
      B12 serum levels, frequency of vitamin B12 deficiency, and related factors among 
      Jordanian patients with T2DM patients treated with metformin. METHODS: a total of 
      447 subjects attending a primary health care center were included in this 
      cross-sectional study consisting of T2DM patients who use metformin and a control 
      group of non-diabetics. Serum B12 levels were evaluated and B12 deficiency was 
      defined as serum B12 levels </= 200 pmol/L. Associations of B12 serum levels or B12 
      deficiency with other factors like gender, age, and duration of T2DM were 
      analyzed. RESULTS: There was no significant difference in serum B12 levels nor 
      the frequency of vitamin B12 deficiency between T2DM metformin-treated patients 
      and control groups. Among metformin-treated patients there was no difference 
      relating to age, type 2 diabetes mellitus duration, proton pump inhibitors use, 
      and metformin use (duration, dose) between patients with or without B12 
      deficiency. CONCLUSION: The prevalence of vitamin B12 deficiency among T2DM 
      patients on metformin treatment in this study was high (48.9%). However, the 
      treatment with metformin and the dose of metformin use was not associated with 
      vitamin B12 deficiency.
CI  - Copyright (c) 2023 Al Quran, Khader, Allan, Al-Momani, Aqel, Alsaleh and Bataineh.
FAU - Al Quran, Thekraiat
AU  - Al Quran T
AD  - Faculty of Medicine, Department of Public Health and Family Medicine, Jordan 
      University of Science and Technology, Irbid, Jordan.
FAU - Khader, Ateka
AU  - Khader A
AD  - Hijjawi Faculty for Engineering Technology, Department of Biomedical Systems and 
      Informatics Engineering, Yarmouk University, Irbid, Jordan.
FAU - Allan, Hadeel
AU  - Allan H
AD  - Faculty of Medicine, Department of Public Health and Family Medicine, Jordan 
      University of Science and Technology, Irbid, Jordan.
FAU - Al-Momani, Rua'a
AU  - Al-Momani R
AD  - Faculty of Medicine, Department of Public Health and Family Medicine, Jordan 
      University of Science and Technology, Irbid, Jordan.
FAU - Aqel, Hamzeh T
AU  - Aqel HT
AD  - Faculty of Medicine, Department of Public Health and Family Medicine, Jordan 
      University of Science and Technology, Irbid, Jordan.
FAU - Alsaleh, Mu'taz
AU  - Alsaleh M
AD  - Faculty of Medicine, Department of Anesthesia and Recovery, Jordan University of 
      Science and Technology, Irbid, Jordan.
FAU - Bataineh, Ziad
AU  - Bataineh Z
AD  - Faculty of Medicine, Department of General Surgery, Jordan University of Science 
      and Technology, Irbid, Jordan.
AD  - Department of General Surgery, Dr. Sulaiman Al Habib Medical Group, Riyadh, Saudi 
      Arabia.
LA  - eng
PT  - Journal Article
DEP - 20230904
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy/epidemiology
MH  - *Metformin/therapeutic use
MH  - Cross-Sectional Studies
MH  - Prevalence
MH  - *Vitamin B 12 Deficiency/epidemiology
MH  - Primary Health Care
PMC - PMC10507406
OTO - NOTNLM
OT  - Jordan
OT  - metformin
OT  - type 2 diabetes mellitus
OT  - vitamin B 12 deficiency
OT  - vitamin B12
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/09/21 06:42
MHDA- 2023/09/22 06:42
PMCR- 2023/01/01
CRDT- 2023/09/21 04:11
PHST- 2023/05/22 00:00 [received]
PHST- 2023/08/18 00:00 [accepted]
PHST- 2023/09/22 06:42 [medline]
PHST- 2023/09/21 06:42 [pubmed]
PHST- 2023/09/21 04:11 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2023.1226798 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2023 Sep 4;14:1226798. doi: 
      10.3389/fendo.2023.1226798. eCollection 2023.